SCHEMBL4765998

SCHEMBL4765998

Cc1n[nH]c(C)c1CCNc1cc(-c2cccnc2)nc(-c2ccccn2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.46
CYP2C9 P11712 1/20 0.46
PTGDR Q13258 3/20 0.43
CYP2A6 P11509 1/20 0.41
PIM1 P11309 4/20 0.40
PIM2 Q9P1W9 3/20 0.40
PIM3 Q86V86 2/20 0.40
SLC2A1 P11166 1/20 0.40
ALK Q9UM73 1/20 0.40
TSHR P16473 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
PKM P14618 1/20 0.39
RAB9A P51151 1/20 0.39
HIF1A Q16665 1/20 0.39
ALDH1A1 P00352 3/20 0.39
CYP1A2 P05177 3/20 0.39
CYP2D6 P10635 3/20 0.39
HSD17B10 Q99714 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2238435 0.83 CYP3A4 (0.44) CYP3A4CYP2C9PTGDRCYP2A6ALDH1A1
SCHEMBL2237967 0.81 CYP3A4 (0.47) CYP3A4CYP2C9PTGDRCYP2A6SLC2A1
SCHEMBL2240945 0.81 GBA1 (0.54) CYP3A4CYP2C9PTGDRCYP2A6SLC2A1
SCHEMBL2238098 0.81 PTGDR (0.53) CYP3A4CYP2C9PTGDRCYP2A6SLC2A1
SCHEMBL4774817 0.80 CYP3A4 (0.46) CYP3A4CYP2C9PTGDRCYP2A6SLC2A1
SCHEMBL2239979 0.80 SPR (0.42) CYP3A4CYP2C9PTGDRALDH1A1CYP1A2
SCHEMBL4773623 0.80 CYP3A4 (0.48) CYP3A4CYP2C9PTGDRCYP2A6SLC2A1
SCHEMBL4769194 0.80 PTGDR (0.46) CYP3A4CYP2C9PTGDRCYP2A6PIM1
SCHEMBL2237320 0.79 HIF1A (0.47) CYP3A4CYP2C9PTGDRCYP2A6SLC2A1
SCHEMBL4768768 0.78 PTGDR (0.53) CYP3A4CYP2C9PTGDRCYP2A6SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1878733-A1 Pyrimidine derivatives as ALK-5 inhibitors Novartis AG (CH) 2008-01-16 EP disclosed